International Stem Cell Corp. (ISCOD) Reports Completion of New Compound’s Clinical Testing
Yesterday, International Stem Cell Corp., a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced the completion of a recently discovered compound’s clinical testing. This compound is expected to be utilized in skin care products marketed by the company’s wholly-owned subsidiary Lifeline Skin Care, Inc.
Topical treatment with the compound showed significant (p<0.01) improvement in skin elasticity and decrease in skin roughness in all subjects 4 and 8 weeks after the start of the study. In addition, the compound-treated group outperformed not only the baseline, but also the Retinol treated group. There were no adverse events reported in the compound-treated group, such as skin irritation, which has been reported as a common side effect of Retinol treatment.
Prior to the clinical study, the compound was tested on different in vitro models: normal human keratinocytes, fibroblasts and 3D model of human skin. In all these models, the recently discovered compound induced up to twice the production of elastin and collagen compared to Retinoic Acid (the active form of Retinol) with none of its toxic characteristics.
The launch of the compound-based products is expected this year. Currently Lifeline markets its stem cell-based skin care in the US and Asia via professional and on-line retail channels (www.lifelineskincare.com). The company believes that these new compound-based products will not only allow it to increase sales and profit margins in its existing markets, but also will allow it to enter the European “high-tech” skin care market.
For more information on International Stem Cell Corp., visit www.internationalstemcell.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
Yesterday, International Stem Cell Corp., a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced the completion of a recently discovered compound’s clinical testing. This compound is expected to be utilized in skin care products marketed by the company’s wholly-owned subsidiary Lifeline Skin Care, Inc.
Topical treatment with the compound showed significant (p<0.01) improvement in skin elasticity and decrease in skin roughness in all subjects 4 and 8 weeks after the start of the study. In addition, the compound-treated group outperformed not only the baseline, but also the Retinol treated group. There were no adverse events reported in the compound-treated group, such as skin irritation, which has been reported as a common side effect of Retinol treatment.
Prior to the clinical study, the compound was tested on different in vitro models: normal human keratinocytes, fibroblasts and 3D model of human skin. In all these models, the recently discovered compound induced up to twice the production of elastin and collagen compared to Retinoic Acid (the active form of Retinol) with none of its toxic characteristics.
The launch of the compound-based products is expected this year. Currently Lifeline markets its stem cell-based skin care in the US and Asia via professional and on-line retail channels (www.lifelineskincare.com). The company believes that these new compound-based products will not only allow it to increase sales and profit margins in its existing markets, but also will allow it to enter the European “high-tech” skin care market.
For more information on International Stem Cell Corp., visit www.internationalstemcell.com
Please see disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.com
